A clinical study to learn about the safety and effects of KIN-2787, a new oral anticancer drug for the treatment of patients with BRAF and/or NRAS Mutation-positive Solid Tumors

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516331-27-00

Acronym

KN-8701/KIN2787CI101

Enrollment

217

Registered

2024-10-15

Start date

2022-06-10

Completion date

Unknown

Last updated

2025-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Participants with BRAF and/or NRAS mutation positive tumors

None listed

Sex/Gender

All

Age

18 Years to No maximum

France, Germany, Italy, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026